pilsicainide has been researched along with Coronary Artery Disease in 1 studies
pilsicainide: structure given in first source
pilsicainide : A secondary carboxamide resulting from the formal condensation of the amino group of 2,6-dimethylaniline with the carboxy group of (tetrahydro-1H-pyrrolizin-7a(5H)-yl)acetic acid. It is a sodium channel blocker which is used as an antiarrhythmic drug for the management of atrial tachyarrhythmias in Japan.
Coronary Artery Disease: Pathological processes of CORONARY ARTERIES that may derive from a congenital abnormality, atherosclerotic, or non-atherosclerotic cause.
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Omichi, C | 1 |
| Fujimoto, N | 1 |
| Kawasaki, A | 1 |
| Kasai, A | 1 |
1 other study available for pilsicainide and Coronary Artery Disease
| Article | Year |
|---|---|
Ischemia-induced Brugada-type ST-segment alternans and Brugada syndrome.
Topics: Adult; Aged; Angioplasty, Balloon, Coronary; Brugada Syndrome; Bundle-Branch Block; Coronary Artery | 2010 |